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Medical Marijuana for Parkinson's
Disease?
Gonzalo A. Carrasco, PhD
Associate Professor
Department of Biomedical Sciences
Cooper Medical School of Rowan University
carrasco@rowan.edu
Camden, NJ

The Problem
• Parkinson disease (PD) is a debilitating neurodegenerative movement and cognitive disorder
caused by the gradual loss of dopamine producing nerve cells located in the substantia nigra (SN)
region of the brain.
• Dopamine is a neurotransmitter that allows nerve cells to communicate with one another.
• NJ has one of the highest rates of PD in the nation which affects more than 25,000 people.
• Current treatments for PD are targeted at symptom relief by compensating for dopamine
deficiency, but they do NOT alter the progressive damage to nerve cells and their circuits.
• Identifying new therapies that halt or slow the progression of PD would be a major advance in the
field and provide a substantial benefit to this patient population.
• A 2020 review of 14 different studies reports that medical marijuana provides a reduction in
tremors, and involuntary or erratic movements in PD.
• We are currently investigating the neuroprotective effects of marijuana-like compounds
(cannabinoids) in PD.
• PD is NOT currently approved in the NJ Compassionate Use Medical Marijuana Act (CUMMA).
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The Approach to the Problem
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Approach 2: Looking at the micro-environment of nerve cells in PD
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• Importantly, our preliminary data indicate that different marijuana compounds reduce
the expression of α-synuclein in neuronal cells (qRTPCR, Western Blots).
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• α-synuclein aggregates (oligomers/protofibrils) are responsible for the neurotoxicity in
Lewy body disorders such as in PD.
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• α-Synuclein is a presynaptic neuronal protein that is linked genetically and
neuropathologically to PD.

α-Synuclein mRNA (% Control)

Approach 1: Looking at the neuroprotective properties of cannabinoids

Marijuana comppounds reduce the
mRNA levels of α-Symnuclein

• The neuronal microenvironment consists, primarily, of vascular elements and glial cells,
all of which appear to change with age.
• Reduced oxygen levels (Hypoxia) is a central factor in brain aging and the development
of age-related neurological diseases such as PD.
• We looked how reduced oxygen levels (hypoxia) modify the activity of cannabinoid
receptors, the brain protein that mediate the effect of marijuana compounds (qrtpcr
and confocal microscopy).
• Our results suggest that hypoxia modifies the expression of cannabinoid receptors and
their interaction with associated proteins in their signaling network.
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The Challenge
• Get funded by local and federal agencies
• We propose to take advantage of mouse models of PD that are approved by the was Michael J. Fox
Foundation to study PD.
• .We are proposing to use behavioral, neurochemical and molecular biology tools to quantify and
characterize the progressive loss of brain cells and development of movement disorders in PD
mice with and without treatment with marijuana-like compounds.
• The specific aims of these proposal are:
• Aim 1 Determine if marijuana-like compounds will prevent or slow the impairment of locomotor activity
and loss of coordination in a well-accepted mouse model of PD
• Aim 2 Identify the molecular mechanism(s) by which marijuana-like compounds regulate the expression
of genetic markers of PD in human and animal brain cell lines (neuronal and glial cells) and from cells
derived from our mouse model of PD.

• The purpose of our research proposal is to provide reliable scientific data to support the use of
medical marijuana in the treatment of PD in the state of NJ.
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